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Abstract
Background: Sudden cardiac death (SCD) accounts for up to half of cardiac mortality. The risk of SCD is heritable but the
underlying genetic variants are largely unknown. We investigated whether common genetic variants predisposing to
arrhythmia or related electrocardiographic phenotypes, including QT-interval prolongation, are associated with increased
risk of SCD.
Methodology/Principal Findings: We studied the association between 28 candidate SNPs and SCD in a meta-analysis of
four population cohorts (FINRISK 1992, 1997, 2002 and Health 2000, n = 27,629) and two forensic autopsy series (The
Helsinki Sudden Death Study and The Tampere Autopsy Study, n = 694). We also studied the association between
established cardiovascular risk factors and SCD. Causes of death were reviewed using registry-based health and autopsy
data. Cox regression and logistic regression models were adjusted for age, sex, and geographic region. The total number of
SCDs was 716. Two novel SNPs were associated with SCD: SCN5A rs41312391 (relative risk [RR] 1.27 per minor T allele, 95%
CI 1.11–1.45, P= 3.461024) and rs2200733 in 4q25 (RR 1.28 per minor T allele, 95% CI 1.11–1.48, P= 7.961024). We also
replicated the associations for 9p21 (rs2383207, RR 1.13 per G allele, 95% CI 1.01–1.26, P= 0.036), as well as for male sex,
systolic blood pressure, diabetes, cigarette smoking, low physical activity, coronary heart disease, and digoxin use (P,0.05).
Conclusions/Significance: Two novel genetic variants, one in the cardiac sodium channel gene SCN5A and another at 4q25
previously associated with atrial fibrillation, are associated with SCD.
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Introduction
Sudden cardiac death (SCD) is a major public health problem,
accounting for 180,000–250,000 deaths per year in the United
States [1]. Up to half of cardiac deaths occur suddenly [1,2], and
in approximately half of SCD cases, death is the first clinical
manifestation of cardiac disease [1]. Therefore, improved risk
stratification is needed. Established risk factors for coronary heart
disease (CHD) predispose to SCD, including: advanced age, male
sex, elevated blood pressure or serum cholesterol, reduced
pulmonary vital capacity, lack of physical activity, smoking,
excessive alcohol consumption, high body mass index (BMI),
diabetes, rapid heart rate, and electrocardiographic abnormalities
[3–5]. In addition to the well established clinical risk factors, a
family history of SCD confers additional risk [6,7] but the genetic
variants underlying the inherited risk component of SCD are
largely unknown.
Rare mutations in potassium and sodium channel genes cause
long QT syndrome (LQTS) [8–10], marked by delayed ventricular
repolarization and increased risk of ventricular tachycardia and
SCD. Common variants in these LQTS genes are associated with
electrocardiographic QT prolongation [11,12], which has been
associated with SCD in the general population [13]. QT-interval
prolongation predisposes the myocardium to early afterdepolar-
izations, which may trigger ventricular arrhythmias, ventricular
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fibrillation, and ultimately SCD [14]. Since QT interval is highly
heritable [15], it may provide an intermediate, continuous trait
suitable for exploring the genetics of SCD. Other potential
candidate variants to influence SCD risk include common variants
associated with electrocardiographic PR interval, prolongation of
which has been shown to be associated with all-cause mortality
[16], and common variants associated with nonfatal arrhythmia
such as atrial fibrillation, which has been reported to predispose to
SCD after acute myocardial infarction [17].
The present study investigated the role of common genetic
variants with recently reported associations with arrhythmia-
related phenotypes, including atrial fibrillation, QT interval and
PR interval, as potential modifiers of SCD risk. We have
previously reported a study focused principally on the genetic
components of QT interval [18]. The previous study analyzed 14
QT-interval-associated single nucleotide polymorphisms (SNPs) in
6,808 individuals from Health 2000 (including the Mini-Finland
sample), experiencing only 116 SCD events. The current study
examined 28 SNPs in a total of 28,323 individuals, experiencing
716 SCD events, and identified two novel SNPs associated with
increased risk of SCD. In addition, an analysis of cardiovascular
risk factors associated with SCD was carried out in four population
cohorts including a total of 27,629 individuals.
Methods
Ethics statement
All included studies were carried out in accordance with the
Declaration of Helsinki and had appropriate ethical approvals
from the Ethics Committee of the National Public Health Institute,
the Epidemiology Ethics Committee of the Helsinki and Uusimaa
hospital region, the Ethics Committee of the Department of
Forensic Medicine, University of Helsinki, the Tampere University
Hospital Ethics Committee, and/or the National Supervisory
Authority for Welfare and Health (Valvira). Written informed
consent was obtained from the participants of the FINRISK and
Health 2000 population studies. In the case of forensic samples
included in The Helsinki Sudden Death Study (HSDS) [19] and
The Tampere Autopsy Study (TASTY) [20], a complete
medicolegal autopsy has to be performed in Finland in all cases
of unexpected out-of-hospital death of a person without a history
of serious disease, or if the person may have died a non-natural
death. This procedure does not need the permission of the
relatives and can be also accomplished even if the relatives are
against the autopsy. At the forensic autopsy, all necessary routine
samples can be taken to find out the cause of death. In the case of
scientific research, the study protocol has to be first approved by
the ethics committee of the hospital and after that permission for
taking study samples from forensic autopsies has to be obtained
from the National Supervisory Authority for Welfare and Health
(Valvira), without need to contact the relatives to obtain informed
consent.
Study materials
The study samples consisted of FINRISK 1992 (n= 6,051),
FINRISK 1997 (n= 8,446), FINRISK 2002 (n= 8,648), and
Health 2000 (n= 9,013, including the Mini-Finland sample,
n = 985) recruited from the Finnish population, as well as of the
HSDS (n= 297) and TASTY (n= 397) series of forensic autopsies.
The clinical characteristics of the study samples are shown in
Table 1 and Table S1. FINRISK is a series of population-based
health examination surveys focused mainly on cardiovascular risk
factors and carried out at 5-year intervals for the age group of 25–
74 years [21]. Each FINRISK cohort was drawn independently of
each other from the population register for each study area. The
sampling was stratified by sex, 10-year age group and study area,
so that the cell size was generally 250 persons. Because FINRISK
samples are independent population samples drawn every five
years from the same geographical areas, it is possible that the same
individual by coincidence ends up participating in more than one
FINRISK survey. On average, 0.8% of participants of a FINRISK
cohort were included by chance in another FINRISK cohort. This
percentage was considered low and therefore unlikely to bias the
analyses. DNA was available from 21,229 FINRISK participants.
The Health 2000 Study is a two-stage stratified cluster sample
collected between 2000 and 2001 and representing the Finnish
population aged$30 years [22]. The Mini-Finland Health Survey
(n = 8,000) was initially conducted between 1978 and 1980
similarly to The Health 2000 Study [23]. Of the Mini-Finland
participants, 985 participated in a follow-up study in 2001. Health
2000 and Mini-Finland cohorts (DNA available for 6,400
individuals) were pooled for analysis, adjusting for study cohort.
HSDS is a series of consecutive forensic autopsies of men aged
35–69 who died out of hospital in Helsinki between 1991 and
1992. The source sample comprised all out-of-hospital deaths of
previously healthy men or those who had not seen a doctor for
more than one year, excluding decomposed or mutilated bodies
[19]. TASTY included consecutive medico-legal autopsies of men
and women #97 years of age performed in the city of Tampere
from 2002 to 2004 [20]. Subjects aged .80 or ,25 years were
excluded from the current study. In the population cohorts,
subjects who became 80 years old during the follow-up were
censored at their 80th birthday. The age cut-offs were applied in
order to increase the specificity of the SCD classification and to
increase the homogeneity between the population cohorts
collected from the general adult population and the series of
forensic autopsies. Electrocardiographic data were available only
from The Health 2000 Study and has been described in a separate
report [18].
Adjudication of causes of death
The causes of death were adjudicated using data from
FINRISK and Health 2000 baseline investigations and prospective
clinical information from the four national health care registries:
the Causes of Death Registry, the Hospital Discharge Registry, the
Drug Reimbursement Registry, and the Pharmacy Database
(Methods S1). In the combined population cohorts, 65.1% of all
SCDs and 75.1% of out-of-hospital SCDs underwent autopsy. In
the entire study (including the autopsy series), 75.9% of SCDs
underwent autopsy. The follow-up extended until the end of 2008,
was based on personal ID codes, and covered 100% of all study
subjects living in Finland (in FINRISK, 99.6% of all participants).
In total, there were 279,758 person-years of follow-up (Table S1).
All deaths occurring in the study cohorts were classified as
probable, possible or unlikely SCD, or death of unknown cause, by
two independent physician reviewers evaluating all cohort baseline
data and prospective follow-up data from the four national
registries. In cases of disagreement, two additional physicians
reviewed the data independently, and final adjudication was
achieved by consensus of all four physicians. Possible and probable
SCDs were pooled for the main analyses. In sensitivity analyses,
only probable SCDs were included. For a detailed description of
case adjudication, see Supporting Information (Methods S1 and
Table S2).
Sensitivity analyses were carried out using cardiac deaths or all-
cause deaths as the outcome. In these analyses, cardiac deaths
were defined as: ICD-10 I00–I52, R96, R98, or R99 (ICD-9 390–
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429, 798, 799) either as the underlying or the immediate cause of
death in the Causes of Death Registry.
The definitions of prevalent CHD and heart failure are
described in Methods S1. Analysis of use of QT-prolonging
medication was based on listings from the website http://www.
qtdrugs.org (Table S3). The category of QT-shortening medica-
tion included only digoxin.
Genotyping and expression analysis
A total of 30 common (minor allele frequency .1%) SNPs were
selected based on recently reported associations with SCD-related
phenotypes, including atrial fibrillation, QT interval and PR
interval (Table S4). Genomic DNA was genotyped using the
Sequenom iPLEX Gold assay (MALDI-TOF mass spectrometry,
MassARRAY Analyzer Compact, Sequenom Inc., San Diego,
CA, USA). For SNPs, quality control thresholds applied were
$90% genotyping success in the combined population materials
and Hardy-Weinberg equilibrium P.0.002 in each study sample.
Of the 30 genotyped SNPs, 28 passed quality control filters;
rs11756440 and rs2074518 were excluded (Table S5). For each
study subject, $80% genotyping success across all passing SNPs
was required for each genotyping pool separately.
Expression analysis of two significant SNPs, rs41312391 and
rs2200733, was performed on RNA samples extracted from
peripheral blood of 510 unrelated individuals aged 25–74 years
(mean 51.9613.7 years, females 53.8%) from the Helsinki region
using Illumina HumanHT-12 Expression BeadChips (Illumina
Inc., San Diego, CA, USA) as described previously [24].
Individuals used in the gene expression analysis represent the
general Finnish population and were not selected for any trait.
Statistical analyses
The QT-interval genotype score (QTscore), which aggregates the
information from 12 QT-interval-associated SNPs (Table S6), was
calculated for each individual as described previously [18]. In
FINRISK and Health 2000 cohorts, a Cox proportional hazards
regression model was applied for analyzing the association
between genotype and time to SCD. Age was used as the time
scale in the Cox model and primary adjustments included sex and
geographic region (East vs. West). In the second model, additional
adjustments were applied for established cardiovascular risk factors
(high-density lipoprotein (HDL)-total cholesterol concentration
ratio, systolic blood pressure, prevalent diabetes, BMI, current and
former smoking, moderate/high vs. low leisure-time physical
activity) and prevalent CHD. Models 3 and 4 adjusted for all
covariates in model 2 as well as for QT-prolonging and QT-
shortening drug use in model 3 and prevalent heart failure in
model 4. An additional model for rs2200733 also adjusted for
atrial fibrillation (Minnesota codes 8.3.1 and 8.3.3) at baseline in
the Health 2000 cohort in addition to the covariates in model 2. In
the forensic autopsy series, the association between genotype and
cause of death (SCD vs. unlikely SCD) was analyzed using logistic
regression adjusting for age at death and sex. An additive
genotypic model (genotypes coded as 0, 1, 2) was used in all
analyses. Similar analyses were also performed for probable SCDs
and all-cause and cardiac mortality adjusting for sex and
geographic region. The association between baseline cardiovas-
cular risk factors (see above) and time to SCD was investigated
with a multivariate model in the population cohorts using Cox
proportional hazards regression.
Analyses were performed with R version 2.11 (‘‘survival’’
package) [25]. Inverse variance-weighted, fixed-effects meta-
analysis (‘‘meta’’ package) was performed for pooling of risk
estimates. Heterogeneity between studies was assessed with I2
statistic [26]. When significant heterogeneity occurred (I2.0.5),
random-effects meta-analysis was applied. The Bonferroni-cor-
rected significance threshold for 25 independent tests (r2,0.5) was
0.002 (P=0.05/25). In secondary analyses, P,0.05 was consid-
ered statistically significant. All tests were two-sided. The power to
observe a hazard ratio of 1.30 in the Cox regression analyses in the
prospective population cohorts (n = 27,629) was 99.1%. For 1-ms
change in the linear QTscore, the corresponding analyses had 80%
power to detect a hazard ratio $1.031 and 90% power to detect a
hazard ratio $1.034.
Results
Cardiovascular risk factors and SCD
Male gender, higher systolic blood pressure, prevalent diabetes,
current and former cigarette smoking, and Eastern Finnish
residency all increased the risk of SCD in the meta-analysis of
FINRISK and Health 2000 population cohorts, whereas increased
leisure-time physical activity reduced the risk (Table 2). Prevalent
CHD and digoxin use were associated with elevated risk of SCD,
but the use of QT-prolonging drugs was not significantly
associated with SCD risk (Table 2).
Table 1. Clinical characteristics of the study samples.
Population cohorts Autopsy studies
FINRISK 1992 FINRISK 1997 FINRISK 2002 Health 2000 HSDS TASTY
N with DNA available 5345 7672 8212 6400 297 397
Source population Finland (4 regions*) Finland (5 regions{) Finland (6 regions{) Finland (the whole
population
aged $30 years)
Finland (region of
Helsinki)
Finland (region of
Tampere)
Age at baseline,
mean 6 SD
44.3611.3 48.4613.4 48.0613.1 53.0613.0 52.269.5 60.5613.0
Sex, male, % 46.3 49.7 46.6 45.9 100 68.5
N of SCD 129 178 75 112 117 105
HSDS = The Helsinki Sudden Death Study, SCD = sudden cardiac death, SD = standard deviation, TASTY = The Tampere Autopsy Study.
*Helsinki/Vantaa, Turku/Loimaa, North Karelia, and North Savo.
{Helsinki/Vantaa, Turku/Loimaa, North Karelia, North Savo, and Oulu province.
{Helsinki/Vantaa, Turku/Loimaa, North Karelia, North Savo, Oulu province, and Lapland.
doi:10.1371/journal.pone.0041675.t001
Common Genetic Variants Associated with SCD
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41675
Common genetic variants associated with SCD
Two SNPs were significantly associated with risk of SCD after
Bonferroni correction: SCN5A rs41312391 (relative risk [RR] 1.27,
95% confidence interval [CI] 1.11–1.45, P=3.461024) and
rs2200733 in 4q25 upstream of the PITX2 gene (RR 1.28, 95%
CI 1.11–1.48, P=7.961024) (Figure 1 and Table 3). The
association results of these two SNPs were consistent among the
different study cohorts (I2 = 0.00). In a sensitivity analysis
restricting the cases to probable SCDs, the RR estimates remained
similar: 1.28 (95% CI 1.11–1.48, P=661024) for rs41312391 and
1.27 (95% CI 1.08–1.49, P=0.003) for rs2200733, implicating
that inclusion of possible SCDs into the phenotype did not bias the
results. In the expression analysis, the minor allele of rs41312391
was associated with increased expression of WDR48 (P=0.037)
and the minor allele of rs2200733 with increased expression of
PITX2 (P=0.013). The previously detected SCD association for
rs2383207 in 9p21 [27] was replicated (RR 1.13, 95% CI 1.01–
1.26, P=0.036). None of the 28 SNPs was associated with all-
cause mortality, but rs2200733 was associated with cardiac
mortality (Table S7). The linear QTscore was not associated with
SCD (P=0.61) in the meta-analysis (Table S8).
SNP associations after adjustment for documented
cardiovascular risk factors
Covariate adjustments in model 2 included sex, geographic
region, cardiovascular risk factors (Table 2), and prevalent CHD.
Use of QT-prolonging and QT-shortening medication were
additionally adjusted for in model 3, and prevalent heart failure
in model 4. Because these additional covariates were not available
in HSDS and TASTY, models 2–4 could not be tested in these
cohorts. SCN5A rs41312391 and 4q25 rs2200733 remained
significant risk factors for SCD in all four models (Table 3 and
Table S9). Adjustment for atrial fibrillation at baseline only slightly
decreased the risk estimate of rs2200733 but the confidence
intervals were wide (Table S9).
Discussion
We studied the association of 28 common candidate SNPs with
SCD in four large population-based cohorts and two forensic
autopsy studies, altogether comprising 716 SCD cases among
28,323 individuals, and performed a meta-analysis combining the
results of individual studies. Two SNPs were significantly
associated with risk of SCD after correction for multiple testing:
rs41312391 in the SCN5A sodium channel gene and rs2200733 in
4q25, which has been associated with atrial fibrillation [28]. In
addition, this study replicates the association of rs2383207 in 9p21
with SCD [27].
Previously reported associations of SCD risk with male gender,
higher systolic blood pressure, prevalent diabetes, current and
former cigarette smoking, leisure-time physical activity, prevalent
CHD, and Eastern Finnish residency were replicated [3–5,19].
High BMI, high total cholesterol and low HDL cholesterol
concentration, as well as the use of QT-prolonging drugs have
been associated with increased risk of SCD in previous studies
[3,5,29]. In the present study, BMI, the HDL/total cholesterol
concentration ratio, and the use of QT-prolonging drugs were not
significantly associated with risk of SCD. Interestingly, use of the
QT-shortening drug digoxin was associated with an increased risk
of SCD. This may be due to the fact that digoxin may have been
prescribed to treat atrial fibrillation or heart failure, both of which
are associated with SCD risk [17,30]. Alternatively, digoxin use
could be directly related to risk of SCD [31].
The SCN5A rs41312391 (IVS24+116G.A) minor allele has
been associated with QT-interval prolongation in normal subjects
in one study (n= 282, P=0.04) [32] and QT-interval shortening in
another (n = 396, P=0.02) [33]. This SNP was not significantly
associated with QT interval in the Health 2000 study (n = 4,802,
b=20.9 ms, P=0.06). In the present study, the minor allele was
found to have a frequency of 20% and to be associated with a 27%
increased SCD risk. Adjusting for other cardiovascular risk factors
and presence of CHD and heart failure at baseline did not reduce
the SCD risk estimate, suggesting that the risk conferred by the
allele may be independent of CHD and heart failure. SCN5A
Table 2. Cardiovascular risk factors associated with SCD in a multivariate model in four population-based cohorts.
Population cohorts, HR (95% CI) Fixed-effects meta-analysis
FINRISK 1992 FINRISK 1997 FINRISK 2002 Health 2000 I2 HR (95% CI) P-value
Sex, male 3.37 (2.24–5.07) 2.34 (1.56–3.52) 3.12 (1.70–5.74) 2.59 (1.62–4.13) 0.00 2.79 (2.23–3.51) ,2.2610216
Geographic region, East 1.43 (1.05–1.95) 1.06 (0.78–1.44) 1.60 (0.92–2.79) 1.19 (0.80–1.76) 0.00 1.26 (1.05–1.51) 0.01
HDL/TC ratio 1.22 (0.11–13.4) 0.08 (0.01–1.08) 0.93 (0.04–23.6) 1.27 (0.08–21.1) 0.00 0.56 (0.15–2.16) 0.40
Systolic BP per 10 mmHg 1.17 (1.08–1.26) 1.06 (0.98–1.13) 1.12 (1.02–1.24) 1.06 (0.97–1.16) 0.35 1.10 (1.06–1.15) 4.861026
Prevalent diabetes 2.26 (1.49–3.44) 1.59 (1.07–2.39) 1.57 (0.85–2.88) 1.49 (0.94–2.37) 0.00 1.74 (1.38–2.18) 2.261026
BMI per kg/m2 1.05 (1.02–1.09) 1.01 (0.97–1.04) 1.04 (0.99–1.09) 0.97 (0.92–1.01) 0.71* 1.02 (0.98–1.06) 0.38
Current smoker 2.70 (1.85–3.94) 2.78 (1.89–4.09) 5.48 (3.04–9.86) 4.83 (2.84–8.22) 0.55* 3.55 (2.52–5.00) 3.9610213
Former smoker 1.21 (0.79–1.84) 1.28 (0.86–1.90) 1.08 (0.56–2.09) 2.36 (1.38–4.02) 0.39 1.39 (1.10–1.76) 0.007
Physical activity{ 0.56 (0.41–0.78) 0.58 (0.42–0.80) 0.42 (0.26–0.66) 0.45 (0.31–0.65) 0.00 0.51 (0.43–0.62) 6.7610213
Prevalent CHD 4.77 (3.20–7.13) 2.70 (1.77–4.11) 3.56 (2.06–6.17) 5.10 (3.38–7.72) 0.47 3.99 (3.20–4.96) ,2.2610216
QT-prolonging drug NA 0.76 (0.40–1.42) 1.29 (0.58–2.84) 0.85 (0.46–1.55) 0.00 0.90 (0.61–1.31) 0.57
Digoxin NA 3.33 (1.98–5.60) 2.12 (0.75–6.01) 2.68 (1.41–5.08) 0.00 2.91 (2.00–4.24) 2.761028
BMI = body mass index, BP = blood pressure, CHD = coronary heart disease, CI = confidence interval, HDL = high-density lipoprotein cholesterol, HR = hazard ratio
(in Cox regression), I2 = measure of heterogeneity between studies, SCD = sudden cardiac death, TC = total cholesterol.
*Random-effects meta-analysis was used because of significant heterogeneity between studies.
{Leisure-time physical activity (moderate/high vs. low).
doi:10.1371/journal.pone.0041675.t002
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encodes the a-subunit of the cardiac sodium channel. Different
mutations in SCN5A are known to cause congenital LQTS,
Brugada syndrome, progressive cardiac conduction disease, sick
sinus syndrome, dilated cardiomyopathy, and atrial fibrillation
[34]. The expression analysis indicated that rs41312391 may
change the expression level of a nearby gene, WDR48, which
encodes a WD repeat-containing protein, a regulator of histone
deubiquitinating complexes. However, SCN5A remains the more
likely candidate gene for SCD due to its known function in
myocardial repolarization and conduction processes that can result
in SCD when deranged.
The minor T allele of rs2200733 at 4q25 has a population
frequency of 16% and was associated with a 28% increased risk of
SCD in our study, independent of the presence of CHD risk
factors at baseline. It was also associated with a 28% increased risk
of cardiac mortality, which implicates that it is also involved in
non-sudden cardiac death. The same allele has been reported to
predispose to atrial fibrillation in populations of both European
and Chinese ancestry [28]. Our additional adjustment model
suggests that the association of rs2200733 with SCD does not
appear to be entirely explained by the increased risk of atrial
fibrillation but may also involve other mechanisms, such as
increased arrhythmia risk or abnormal cardiac function in general.
Figure 1. Forest plot of SCD risk ratios for rs41312391 and rs2200733. The figure shows point estimates for relative SCD risk (squares, area
proportional to the inverse-variance weight) and 95% confidence intervals (horizontal lines) in all six cohorts, adjusting for sex and geographic region.
The lateral tips of the diamonds indicate the 95% confidence intervals for the relative risk and the widest point of the diamond the relative risk
estimate in the meta-analysis. HSDS = The Helsinki Sudden Death Study, SCD = sudden cardiac death, TASTY = The Tampere Autopsy Study.
doi:10.1371/journal.pone.0041675.g001
Table 3. Results of the SCD meta-analysis for the two significant SNPs.
SNP Model Population cohorts, HR (95% CI)
Autopsy studies, OR (95%
CI) Fixed-effects meta-analysis
FINRISK 1992 FINRISK 1997 FINRISK 2002 Health 2000 HSDS TASTY I2 RR (95% CI) P-value
rs41312391 1 1.43 (1.09–1.87) 1.32 (1.04–1.68) 1.41 (0.97–2.04) 1.05 (0.76–1.46) 1.20 (0.78–1.83) 1.09 (0.72–1.62) 0.00 1.27 (1.11–1.45) 3.461024
rs41312391 2 1.53 (1.16–2.01) 1.33 (1.03–1.73) 1.44 (0.99–2.08) 1.07 (0.76–1.50) NA NA 0.00 1.35 (1.16–1.57) 1.261024
rs2200733 1 1.15 (0.83–1.59) 1.15 (0.88–1.49) 1.55 (1.04–2.32) 1.42 (1.02–1.98) 1.12 (0.71–1.78) 1.58 (1.00–2.50) 0.00 1.28 (1.11–1.48) 7.961024
rs2200733 2 1.06 (0.77–1.47) 1.23 (0.93–1.63) 1.67 (1.11–2.50) 1.30 (0.92–1.82) NA NA 0.00 1.26 (1.07–1.49) 0.006
Model 1: Age was used as the time scale and sex and geographic region were adjusted for. Model 2: Sex, geographic region, HDL-total cholesterol ratio, systolic blood
pressure, prevalent diabetes, BMI, current and former smoking status, physical activity, and prevalent CHD were adjusted for. BMI = body mass index, CHD = coronary
heart disease, CI = confidence interval, HDL = high-density lipoprotein cholesterol, HR = hazard ratio (in Cox regression), HSDS = The Helsinki Sudden Death Study, I2
= measure of heterogeneity between studies, OR = odds ratio (in logistic regression), RR = relative risk, SCD = sudden cardiac death, SNP = single nucleotide
polymorphism, TASTY = The Tampere Autopsy Study.
doi:10.1371/journal.pone.0041675.t003
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However, a possibility of residual confounding also exists, since
atrial fibrillation may not always have been captured by the
baseline electrocardiogram. The expression analysis indicated that
rs2200733 is associated with the expression of PITX2, the nearest
gene in this chromosomal region. PITX2 is a transcription factor
known to direct the left-right asymmetry in cardiac development
[35] and to contribute to sinoatrial node formation [36]. PITX2
expression level is associated with structural and electrical changes
in the atrial chambers, as well as expression of ion channel genes,
including SCN5A [37]. Our results show that PITX2 represents a
novel candidate gene for both SCD and non-sudden cardiac
death.
The minor G allele of rs2383207 on chromosome 9p21 has
previously been associated with a 25% increased risk of
myocardial infarction [38] and a 23% increased risk of SCD
[27]. Our study replicates this association for SCD. The nearest
genes in this 9p21 chromosomal region are the cyclin-dependent
kinase inhibitor genes CDKN2A and CDKN2B as well as the
CDKN2B antisense RNA gene. Deletion of the orthologous
chromosomal region in mice leads to reduced expression of
CDKN2A and CDKN2B as well as to excessive proliferation and
diminished senescence of aortic smooth muscle cells [39].
Accordingly, it has been suggested that the variants in the 9p21
region predispose to CHD by affecting vascular remodeling [39].
Of the 28 candidate SNPs investigated in the present study, 25
did not show a statistically significant association with SCD. The
power to identify a hazard ratio of .1.30 in the population
cohorts was high (.99%) but this study cannot exclude the
possibility of an association with a more modest effect size.
Therefore, larger meta-analyses are needed to assess the role of
candidate gene variants that may increase the risk of SCD by
acting through arrhythmia-related intermediate phenotypes.
However, this study was able to demonstrate the potential of
identifying novel SCD-associated variants using suitable interme-
diate phenotypes for selection of candidate variants. When
investigating the QT-prolonging variants in aggregate, the present
study did not demonstrate an association between the linear
QTscore and SCD, nor did it replicate the previously reported
finding of an increased risk of SCD at the top compared to the
median quintiles of QTscore [18]. Failure to detect an association
could reflect a complex interaction between QT-prolonging and
QT-shortening variants and risk of SCD or could be caused by
inadequate power to detect a modest effect on SCD risk.
This study explored the association of a wide selection of
candidate SNPs with SCD in a large sample collection of four
population cohorts and two series of forensic autopsies, including a
total of 716 SCD events. A strength of the present study is the
availability of large prospective population cohorts enabling more
precise risk estimates than case-control studies. In addition,
prospective studies enable exploration of the effects of covariate
adjustment. The long-term follow-up of the study subjects was
comprehensive covering all subjects living in Finland, the autopsy
rate of SCD cases was high (75.9%), and extensive information on
the causes of death was gathered through several national
registries. In Finland, autopsies are targeted on cases in which
clinical information is insufficient to determine the cause of death.
As the diagnoses in the death certificate are generally valid,
including cases without autopsy [40,41], the information obtained
from the national registries as well as from the baseline
investigations can be considered sufficient for reliable classification
of causes of death. Finns represent a genetically isolated
population with significant substructure due to founder effects
and bottlenecks during the settlement history [42]. Significant
East-West differences have previously been reported in the risk of
SCD [19] and we replicated this finding. To account for
population stratification in the present study, geographic region
(East vs. West) was adjusted for in the statistical analyses of the
population cohorts.
A large proportion of SCDs in Western countries are
unwitnessed and therefore the presence of an underlying fatal
arrhythmia, and the time between onset of symptoms and death
cannot be reliably determined in a population-based study. The
inclusion of individuals with a wide age range (25–80 years)
increases the generalizability of the study but at the expense of
increasing heterogeneity of the causes of death. Limitations of the
study include also incomplete SNP information for constructing
the QTscore, missing covariate information in the forensic autopsy
materials, and missing registry-based medication information
before year 1995 (FINRISK 1992). Covariate information was
available at baseline, which could be many years earlier than the
date of death.
Conclusions
We report two novel SNPs associated with increased risk of
sudden cardiac death (SCD). In addition, our results replicate the
association of a SNP in the chromosomal region 9p21 with SCD.
Our study replicates the previously reported associations between
well-known cardiovascular risk factors and risk of SCD. The novel
findings of this study add to our understanding of the contributions
of common genetic variants to SCD risk.
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